Clopidogrel is an irreversible P2Y12 ADP-receptor antagonist that prevents platelet aggregation, used for secondary prevention of atherothrombotic events in patients after myocardial infarction, stroke or established peripheral arterial disease. Simson Pharma's Clopidogrel Hydrochloride reference standard and impurities support the high-volume compendial testing this major cardiovascular generic demands.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Clopidogrel Hydrochloride Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.